Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 7/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.38 |
| ▸ | BCL2 | P10415 | 4/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.37 |
| ▸ | BAD | Q92934 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6020147 | 0.89 | L3MBTL1 (0.44) | STING1ACHEL3MBTL1KDM4EMEN1 | |
| SCHEMBL6020606 | 0.81 | STING1 (0.44) | STING1ACHEL3MBTL1 | |
| SCHEMBL6021022 | 0.78 | STING1 (0.49) | STING1ACHEL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4768124 | 0.77 | STING1 (0.45) | STING1ACHEL3MBTL1 | |
| SCHEMBL4762895 | 0.75 | NPC1 (0.42) | STING1ACHEKDM4EMEN1ALDH1A1 | |
| SCHEMBL6021329 | 0.73 | STING1 (0.47) | STING1ACHEL3MBTL1PIK3CD | |
| SCHEMBL6020839 | 0.73 | STING1 (0.47) | STING1ACHEKDM4EMEN1ALDH1A1 | |
| SCHEMBL6021255 | 0.72 | STING1 (0.46) | STING1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6021540 | 0.72 | STING1 (0.46) | STING1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL5224932 | 0.72 | STING1 (0.69) | STING1MCL1BCL2L1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636210-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | CONNOLLY MICHAEL KEVIN (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004108713-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | MALT1, CYP1B1, WEE2 | STING1 2586/4885ACHE 4370/4885MCL1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.